Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma.
‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- What are the limitations of current biologic therapies for asthma? (0:18)
- What makes tezepelumab unique among biologic treatments for moderate-to severe asthma? (2:23)
- What have the NAVIGATOR and SOURCE studies taught us about the efficacy and safety of tezepelumab in this treatment setting? (3:45)
- What are the aims and design of the CASCADE study? (5:37)
- What are the primary and secondary outcome measures of this study and how well were these achieved? (7:38)
Disclosures: Sarah Diver has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).